Our Cells

RESTEM has developed world-leading cellular therapeutics to evolve innovative allogeneic cellular medicines to treat complex inflammatory diseases.

More info

COVID19 Response

RESTEM is committed to the development of technologies that ensure our world’s health and wellbeing.
Presently, we are in clinical studies for COVID19 presenting solutions for unmet needs.

Clinical Trials

We are proud donors of cGMP stem cells for clinical studies. Presently, moving forward with clinical studies on Autoimmune diseases, COVID19, Duchenne Muscular Dystrophy and Heart Failure secondary issues following left ventricular assisted.

More info

News

FDA approves COVID-19 treatment after successful use of STEM CELLS from RESTEM
May 14, 2020

CORONA, Calif., and MIAMI and SIOUX FALLS, S.D., May 14, 2020 — RESTEM, a leading cell-based therapeutics company, announced [...]

Patient Credits Stem Cell Treatment With Saving Her Life
May 8, 2020

MIAMI (CBSMiami) – The U.S. Food and Drug Administration gave Baptist Health approval to test a stem [...]

Florida Mom Recovers From Covid-19 with Stem Cell Therapy
May 8, 2020

A single mom in Florida’s sweet reunion with her two children was captured on video [...]

3 Miami COVID-19 Patients Successfully Recovered with Stem Cell Therapy
May 7, 2020

 A team of South Florida doctors have successfully treated three critically ill COVID-19 patients with [...]

COVID-19: Three Patients Successfully Treated with RESTEM Stem Cells
May 7, 2020

RESTEM, a leading-edge biotechnology company, and Baptist Health South Florida, today announced three COVID-19 patients with acute [...]

Announcements

Restem
December 4, 2019

RESTEM to donate its proprietary ULSCs in an approved investigational new drug application phase I [...]

University of Murcia
September 1, 2019

University of Murcia, Spain commences preclinical umbilical cord lining stem cells (ULSCs) animal work on [...]

University of Murcia
July 18, 2019

University of Murcia, Spain completes preclinical umbilical cord lining stem cells (ULSCs) animal work illustrating [...]

Restem
January 6, 2019

RESTEM acquires umbilical cord lining stem cells (ULSCs) technology rights in full to include all [...]

Our Partners

We are proud to collaborate with some of the leading health research institutes in the development of best in class cellular therapeutics to evolve human health.